Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study-Reference-Cited by-同舟云学术

Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study

Published:2020-08-26 Issue:3 Volume:17 Page:723-730
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Asatryan Asmik¹,Meyer Nadia²,Scherbakov Michael³^ORCID,Romanenko Victor⁴,Osipova Irina⁵,Galustyan Anna⁶⁷,Shamsheva Olga⁸,Latysheva Tatiana⁹,Myasnikova Tatyana⁹,Baudson Nathalie¹⁰,Dodet Monique¹⁰,Xavier Stebin²,Harrington Lauriane²,Kuznetsova Anastasia²,Campora Laura²,Van den Steen Peter²^ORCID

Affiliation:

1. Hospital Stomamedservice, Gatchina, Russian Federation

2. GSK, Wavre, Belgium

3. GSK, Moscow, Russia

4. Children’s City Hospital No11, Ekaterinburg, Russian Federation

5. Ooo “Asko-med-plus”, Barnaul, Russian Federation

6. Medical Technologies Ltd, St. Petersburg, Russian Federation

7. Federal State Budgetary Educational Institution of Higher Education, St. Petersburg State Pediatric Medical University of the Ministry of Healthcare of the Russian Federation, St. Petersburg, Russian Federation

8. Pirogov Russian National Research Medical University, Moscow, Russian Federation

9. NRC Institute of Immunology FMBA, Moscow, Russia

10. GSK Vaccines, Rixensart, Belgium

Funder

GlaxoSmithKline

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1796423

Reference36 articles.

1. Centers for Disease Control and Prevention (CDC) 2015. Epidemiology and prevention of vaccine-preventable diseases, 13th edition; 2015 April. [accessed 2019 Sept 3]. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf.

2. Expert opinion on childhood immunisation schedule: diphtheria-tetanus-pertussis (DTP) vaccination. 2009 Nov 6. [accessed 2019 Sept 3]. https://www.ecdc.europa.eu/en/publications-data/expert-opinion-childhood-immunisation-schedule-diphtheria-tetanus-pertussis-dtp.

3. An update of the global burden of pertussis in children younger than 5 years: a modelling study

4. Pertussis Disease Burden in the Household: How to Protect Young Infants

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and safety of concomitant administration of the sabin-strain-based inactivated poliovirus vaccine, the diphtheria-tetanus-acellular pertussis vaccine, and measles-mumps-rubella vaccine to healthy infants aged 18 months in China;International Journal of Infectious Diseases;2023-12

2. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4–65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany;Vaccine;2023-11

3. Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India;Expert Review of Vaccines;2023-03-13

4. Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting;Current Pain and Headache Reports;2022-11-23